Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

European funding for two research projects with application potential

No. 28 | 05/05/2020 | by Koh

With its "Proof of Concept" grants, the European Research Council ERC supports scientists to further develop the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ), Mathias Heikenwälder and Nina Papavasiliou, are now receiving the coveted funding. Both researchers want to advance the development of antibodies: as research reagents and for cancer prevention.

Nina Papavasiliou
© Jutta Jung / DKFZ

What is special about the ERC's "Proof of Concept" Grants is that this funding can only be applied for by those who already receive ERC grants. The Research Council thus wants to enable scientists to open up possible fields of application for their research results obtained in an ERC-funded project. "At the DKFZ, it is our declared goal to consistently check all scientific results for applicability and usability. This applies both to possible medical improvements that should benefit patients as quickly as possible and to the commercial exploitation, for example of improved research reagents," says Michael Baumann, Director of the DKFZ.

Nina Papavasiliou (ERC Consolidator Grant 2016) is investigating particular modifications in RNA molecules, the significance of which is still poorly understood: messenger RNAs (mRNA), the transcripts of genes, often contain modified building blocks. Scientists suspect that cells use these modifications as an additional control level to regulate the amount of protein whose blueprint is read from the respective gene. To better understand the actual role of these modifications in healthy and diseased cells, a simple but highly specific detection method is required. Previously available antibodies against the modified RNA building blocks often reacted unspecifically or were unable to bind sufficiently tightly to their target structure. Nina Papavasiliou has developed an immunisation system in her laboratory that is particularly suitable for generating high-quality and at the same time highly specific antibodies. With this system, the scientist plans to generate antibodies against the most common RNA modifications. Nina Papavasiliou is convinced that a suitable detection method will help to better understand the mysterious role of the modified RNA building blocks.

Mathias Heikenwälder
© Jutta Jung / DKFZ

Mathias Heikenwälder (ERC Consolidator Grant 2016) also receives ERC PoC funding for the development of specific antibodies. The inflammation expert recently discovered that platelets migrating into the liver promote the development of a certain type of liver inflammation (NASH, non-alcoholic steatohepatitis), which in turn can degenerate into cancer. Drugs that are directed against the platelets can stop this process and thus prevent the development of liver cancer in mice, as Heikenwälder has already been able to show. Inflammatory fatty liver occurs less frequently in people who take these drugs. However, the drugs directed against blood platelets sometimes have serious side effects. Heikenwälder and colleagues have identified an enzyme on the surface of the platelets that is responsible for the development of the inflammation. The researchers' goal is now to generate therapeutic antibodies that specifically inhibit this enzyme. This could interrupt the dangerous cascade of inflammation and carcinogenesis without at the same time impairing the vital function of the blood platelets - blood clotting. In the long term, Heikenwälder and his colleagues hope to be able to contribute to the prevention of liver cancer with a suitable antibody.

Pictures of Nina Papavasiliou and Mathias Heikenwälder are available for download 

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Jutta Jung / DKFZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: Any commercial use is prohibited.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS